The Centers for Disease Control’s (CDC) early estimates of the effectiveness of the seasonal influenza vaccine is 62%.
The Centers for Disease Control’s (CDC) early estimates of the effectiveness of the seasonal influenza vaccine is 62%.
“This interim estimate indicates moderate effectiveness,” CDC stated in its recent Morbidity and Mortality Weekly Report. At the same time, vaccination reduced the risk for flu-related medical visits by approximately 60%.
As of January 11, 2013, 24 states and New York City were reporting high levels of influenza-like illness, 16 states were reporting moderate levels, and 5 states were reporting low levels. More than 128 million doses of flu vaccine has been distributed in the United States for the 2012-2013 season by January 4, out of an estimated 135 million doses that were anticipated to be available for the US market, according to CDC.
“As this time, some vaccine providers might have exhausted their vaccine supplies. Persons seeking vaccination might have need to call more than one provider to locate vaccine,” CDC stated.
While CDC recommends that the annual influenza vaccination efforts continue as long as flu viruses are circulating, the early estimates “underscore that some vaccinated persons will become infected with influenza,” according to MMWR. “Therefore, antiviral medications should be used as recommended for treatment in patients, regardless of vaccination status,” CDC said.
The early results also highlight the importance of continued efforts to develop more effective vaccines.
For its early estimate-which is similar to an estimate from a metaanalysis of randomized controlled clinical trial data-CDC analyzed data from 1,155 adults and children with acute respiratory infection from December 3, 2012, through January 2, 2013.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More